Lumetry Diagnostics: Bringing Quantitative Lung Monitoring Into the Home

Chronic respiratory diseases are among the most under-monitored high-burden conditions globally. COPD alone affects more than 300 million people worldwide and is a leading cause of hospitalization, readmission, and avoidable mortality. Yet longitudinal monitoring of ventilation, especially CO₂ retention, remains largely confined to hospital settings.

This creates a structural gap: patients deteriorate at home while objective respiratory data remains unavailable to clinicians.

Lumetry Diagnostics GmbH is building toward a distributed model of lung function tracking by combining capnography, spirometry, and app-based analytics into a single home-use platform.

The Clinical Problem:

• COPD and severe asthma patients frequently develop hypercapnia (CO₂ retention)

• Early detection requires capnometry, typically unavailable outside clinics

• Symptom-based self-assessment is unreliable and delays intervention

The Device Thesis:

Lumetry’s handheld system measures end-tidal CO₂ during natural breathing, delivering quantitative ventilation data without invasive sampling.
Planned AI models aim to estimate arterial CO₂ (paCO₂), a clinically relevant biomarker for respiratory failure risk.

Why it Matters:

• Enables daily, objective lung monitoring at home

• Supports earlier therapeutic adjustments

• Reduces emergency admissions driven by late detection

For providers, this shifts respiratory care from episodic testing to continuous physiological surveillance.

Traction and Positioning: Based in Graz with clinical collaborations across Central Europe, Lumetry is targeting COPD first, with expansion pathways into asthma, long-COVID, and home sleep-adjacent monitoring.

If AI-based paCO₂ estimation reaches clinical reliability, home capnography could become a new standard in chronic respiratory care. Lumetry’s direction reflects a broader shift: lung disease management moving from periodic testing to continuous, data-driven control.